Publication: Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
Open/View Files
Date
2015
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
BioMed Central
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Powderly, J., G. Cote, K. Flaherty, R. Z. Szmulewitz, A. Ribas, J. Weber, D. Loo, et al. 2015. “Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3.” Journal for Immunotherapy of Cancer 3 (Suppl 2): O8. doi:10.1186/2051-1426-3-S2-O8. http://dx.doi.org/10.1186/2051-1426-3-S2-O8.
Research Data
Abstract
Description
Other Available Sources
Keywords
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service